Acute Hepatic Porphyria (AHP)
American Association for the Study of Liver Diseases (AASLD) 2026
Congress Details
November 5-9, 2026
Denver, CO, USA
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Agenda
05 November, 2026
Presentation Type
Time
Location
Title
Presenter
Akshata Moghe
University of Texas Health Science Center at Houston
TX, USA
06 November, 2026
Presentation Type
Time
Location
Title
Presenter
Susana Monroy Santoyo
Centro Médico ABC
Mexico City, Mexico
08 November, 2026
Presentation Type
Time
Location
Title
Presenter
Bruce Wang
UCSF Medical Center
CA, USA
Related Materials
Acute Hepatic Porphyria (AHP)
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study
Molecular Genetics and Metabolism Reports
Acute Hepatic Porphyria (AHP)
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study
Orphanet Journal of Rare Diseases
Acute Hepatic Porphyria (AHP)
High disease burden and healthcare resource usage in patients with acute porphyria—A population-based analysis
Liver International
Acute Hepatic Porphyria (AHP)
A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort
Journal of the Formosan Medical Association
